Economic Implications of Extended-Release Metoprolol Succinate for Heart Failure in the MERIT-HF Trial: A US Perspective of the MERIT-HF Trial
| Autor: | Kristin Migliaccio-Walle, William Nova, John Wikstrand, Stephen S. Gottlieb, Eric M. Hillson, Jennifer Kim, Ole Hauch, J Jamie Caro, Judith A. O'Brien, Hans Wedel, Prakash Deedwania, Åke Hjalmarson |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Cost-Benefit Analysis Metoprolol Succinate Adrenergic beta-Antagonists Population Improved survival Internal medicine Humans Medicine In patient Hospital Mortality Prospective Studies Hospital Costs Intensive care medicine education Aged Randomized Controlled Trials as Topic Metoprolol Aged 80 and over Heart Failure education.field_of_study business.industry Reproducibility of Results Middle Aged medicine.disease Survival Analysis United States Hospitalization Treatment Outcome Merit hf Delayed-Action Preparations Heart failure Cardiology Female Extended release Cardiology and Cardiovascular Medicine business Models Econometric medicine.drug |
| Zdroj: | Journal of Cardiac Failure. 11:647-656 |
| ISSN: | 1071-9164 |
| DOI: | 10.1016/j.cardfail.2005.06.433 |
| Popis: | Background The MERIT-HF trial demonstrated improved survival and fewer hospitalizations for worsening heart failure with extended-release (ER) metoprolol succinate in patients with heart failure. This study sought to estimate the economic implications of this trial from a US perspective. Methods and Results A discrete event simulation was developed to examine the course of patients with heart failure. Characteristics of the population modeled, probabilities of hospitalization and death with standard therapy, and risk reductions with ER metoprolol succinate were obtained from Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) and evaluated in weekly cycles. Direct medical costs were estimated from US databases in 2001 US dollars. Uncertainty in inputs was incorporated and analyses were carried out to estimate events prevented total and net costs. The model predicts that ER metoprolol succinate will prevent approximately 7 deaths and 15 hospitalizations from heart failure per 100 patients over 2 years. Compared with standard therapy alone, this translates to a cost reduction between $395 and $1112 per patient, depending on whether the costs of hospitalizations for other causes are included. Savings were maintained in 90% of the simulations. Conclusion This analysis predicts that the positive effect of ER metoprolol succinate on mortality and morbidity demonstrated in MERIT-HF leads to substantial savings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect